ÎÚÑ»´«Ã½

Learn About Time Off Treatment with a BCL-2 Inhibitor-based Regimen for CLL/SLL

Sponsored by AbbVie

For in-person participants only

Beyond the Data: Long-Term Efficacy & Safety Integrated Analyses and a Patient's Journey with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sponsored by Apellis Pharmaceuticals

For in-person participants only

This session will include a patient perspective

CAR T Cell Therapy for Second-line (2L) LBCL

Sponsored by Bristol Myers Squibb

For in-person participants only

Learn about an alternative treatment for certain B-cell malignancies. This program is sponsored by Lilly USA, LLC.

Sponsored by Eli Lilly and Company

For in-person participants only

A New Treatment Strategy in cGVHD

Sponsored by Incyte Corporation

For in-person participants only

Choosing a Different Approach: Clinical and Nonclinical Factors for Adults with PNH on FABHALTA

Sponsored by Novartis Pharmaceuticals Corporation

This session will include a patient perspective.

Getting Started and Transitioning to Outpatient Care for Patients With Relapsed or Refractory Multiple Myeloma

Sponsored by Pfizer Oncology

For in-person participants only

Options When a Matched Allogeneic-HCT Source is Not Available

Sponsored by Gamida Cell

For in-person participants only

Unlocking the Potential for a Bispecific Antibody in 3L+ DLBCL and 3L+ FL

Sponsored by Genmab and AbbVie

For in-person participants only

Redefining Frontline Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Sponsored by Johnson and Johnson

For in-person participants only

The Science Behind HYMPAVZI (Marstacimab-hncq): Introducing an Innovative Treatment Option from Pfizer

Sponsored by Pfizer

For in-Person participants only

Transforming aTTP/iTTP Treatment and Management

Sponsored by Sanofi

For in-person participants only

A First-Line Treatment Option for Adults with Symptomatic Anemia Due To Lower-Risk MDS

Sponsored by Bristol Myers Squibb

For in-person participants only

Discover the exciting details about a BCMA Bispecific for 4L+ RRMM

Sponsored by Johnson and Johnson

For in-person participants only

Addressing Critical Unmet Needs With Newly Diagnosed Ph+CML-CP

Sponsored by Novartis

For in-person participants only

Discover Gene Therapy as a Treatment Option for Hemophilia B

Sponsored by Pfizer

For in-person participants only

A first-in-class treatment for RRMM patients

Sponsored by Johnson and Johnson

For in-person participants only

A Different Option in the Treatment of Transfusion-Dependent Anemia in Lower-Risk MDS

Sponsored by Geron

What's Next for Patients with 2L+ Relapsed or Refractory Multiple Myeloma?

Sponsored by Johnson and Johnson

For in-person participants only